Please select the option that best describes you:
How would you approach systemic therapy for a postmenopausal female with metastatic ER+/HER2+ breast cancer (liver/bone) who achieved a CR for 5 years on trastuzumab/pertuzumab and exemestane, with continued asymptomatic brain progression?
Asymptomatic brain progression despite CNS surgery and SRS x2 over the past 2 years.
Answer from: Medical Oncologist at Community Practice
Switch to tucatanib, capecitabine, and trastuzumab. Consider returning to trastuzumab/pertuzumab based treatment at future systemic progression since currently there's no systemic progression.
Consider continuing exemestane. This could be based on recent NSABP trials showing no detriment to concomi...
Sign in or Register to read more